Understanding Patients with Metastatic Breast Cancer – A Preference for Oral Treatments
Washington DC, February 21, 2024 - Ipsos, in collaboration with Living Beyond Breast Cancer and funded by Eli Lilly and Company, conducted research to understand the experiences of patients living with ER+, HER2- metastatic breast cancer.
Most ER+, HER2- metastatic breast cancer patients surveyed would prefer taking oral medications at home instead of traveling to a medical facility to receive an intramuscular injection. Findings from this research highlight the time-burden patients face when attending oncologist appointments; typically, patients commit over 2 hours to attend appointments and, on average, travel 25 miles. These appointments may require patients to adapt their schedule, including taking time off from work and rearranging other personal appointments. Learn more.
Be sure to also revisit our on demand deep dive webinar for more insights from this research.
About the Study
This research program included a primary quantitative survey component, followed by a qualitative social listening exercise.
The survey was conducted between August 23-October 18, 2023. For this survey, a sample of n=100 women with estrogen receptor positive (ER+), HER2-negative metastatic breast cancer between the ages of 35-75 from the continental U.S, Alaska, and Hawaii was interviewed online in English. The sample was randomly drawn from Ipsos’ online panel partners. To qualify for the survey, respondents needed to be currently receiving systemic treatment for their breast cancer under an oncologist’s care but have no prior usage of the intramuscular injection fulvestrant, in addition to the sample qualifications listed above.
The Social Intelligence component was conducted by mining data from ER+, HER2- breast cancer patients from social, forum and mainstream media sources using Ipsos’ Synthesio as well as search services Google Trends and Answer the Public from March 12th, 2022—March 13th, 2023. Social Media sites used included X (formerly Twitter), Facebook, YouTube, Instagram, blogs, and forums, including Reddit. No data weighting was implemented for either portion of the study, and the survey findings and qualitative insights reflect the opinion of these respondents only.
For more information on this news release, please contact:
Matthew Cromley
Director, US
Healthcare
+1 862 222-3743
[email protected]
Noelle Crouchley
Sr. Account Manager, US
Healthcare
[email protected]
About Ipsos
Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.
Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.
Our tagline "Game Changers" sums up our ambition to help our 5,000 customers move confidently through a rapidly changing world.
Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com
